Geron Aims For Fall Return To The Clinic
This article was originally published in Pharmaceutical Approvals Monthly
Geron was the first stem cell therapy company to the clinic, with a plan to inject OPC1, made of embryonic glial progenitor cells, into the spinal cords of paralyzed patients. The idea is that once injected at the site of the nerve damage, the oligodendrocytes go to work rebuilding the insulating myelin sheath around the nerves and produce nerve growth factors called neutrophins that stimulate regrowth of nerve tissue.
You may also be interested in...
After being delayed since May, Geron’s 21,000-page application clears overnight in the first week of the Obama administration.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011